t(1;19)(q23;p13) TCF3-PBX1 May Not Be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated With MRD-Oriented Protocols from the PETHEMA Group

Authors :: Ribera, J
Morgades, M
Granada, I
Torrent, A
Zamora, L
Gonzalez, T
Ciudad, J
Barrena, S
Such, E
Avetisyan, G
Calasanz, MJ
Genesca, E
Gonzalez-Gil, C
Fuster-Tormo, F
Mercadal, S
Maluquer, C
Coll, R
Gonzalez-Campos, J
Tormo, M
Garcia-Cadenas, I
Nomdedeu, J
Gil, C
Cervera, M
Escoda, L
Montesinos, P
Barba, P
Esteve, J
Diaz-Beya, M
Martinez-Sanchez, P
Martinez-Lopez, J
Novo, A
Queipo, MP
Bermudez, A
Bergua, J
Olave, MT
de Rueda, B
Artola, MT
Hernandez-Rivas, JM
Orfao, A
Ribera, JM
Source :: Clinical Lymphoma Myeloma & Leukemia, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, instname
Publication Year :: 2021
Publisher :: Cancer Media Group, 2021.

Subjects :: TCF3-PBX1
PETHEMA
outcome
MRD-oriented trials
acute lymphoblastic leukemia

ISSN :: 21522650
Database :: OpenAIRE
Journal :: Clinical Lymphoma Myeloma & Leukemia, r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol, instname
Accession number :: edsair.RECOLECTA.....f5cdbf6961409d5b5c2799191eb9d990

Tools